Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor-positive Metastatic Breast Cancer|HER2-negative Metastatic Breast Cancer
Interventions: DRUG: Abemaciclib + Aromatase Inhibitor|DRUG: Abemaciclib + Fulvestrant
Sponsor: Prof. Wolfgang Janni
Collaborators: Eli Lilly and Company